Systematic review and meta-analysis comparing the surgical outcomes of invasive intraductal papillary mucinous neoplasms and conventional pancreatic ductal adenocarcinoma

Annals of Surgical Oncology

Volumn 21, Issue 8, 2014, Pages 2782-2800

  Koh, Ye Xin ^a   Chok, Aik Yong ^a   Zheng, Hui Li ^b   Tan, Chuen Seng ^b   Goh, Brian K P ^a,c  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; COLLOID CARCINOMA; COMPARATIVE STUDY; HUMAN; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; INVASIVE INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM; LYMPH NODE METASTASIS; META ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PERINEURAL INVASION; SYSTEMATIC REVIEW; TUMOR VOLUME; ADENOCARCINOMA, MUCINOUS; CARCINOMA, PANCREATIC DUCTAL; CARCINOMA, PAPILLARY; PANCREATIC NEOPLASMS; PATHOLOGY; PROGNOSIS; TUMOR INVASION;

ADENOCARCINOMA, MUCINOUS; CARCINOMA, PANCREATIC DUCTAL; CARCINOMA, PAPILLARY; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS;

EID: 84905104353     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3639-0     Document Type: Article

References (44)

1. Kloppel G, Solcia E, Longnecker DS, Capella C, Sobin LH. Histological typing of exocrine pancreas. Berlin. Springer; 1996.
2. Goh BK, Tan YM, Cheow PC, et al. Cystic neoplasms of the pancreas with mucin-production. Eur J Surg Oncol. 2005;31:282-287. (Pubitemid 40361519)
3. Goh BK, Tan YM, Chung YF, et al. A review of mucinous cystic neoplasms of the pancreas defined by ovarian-type stroma: clinicopathologic features of 344 patients. World J Surg. 2006;30(12):2236-45. (Pubitemid 44885181)
4. Longnecker DS, Adler G, Hruban RH, Kloppel G. Intraductal papillary-mucinous neoplasms of the pancreas. In: Hamilton SR, Bltonen LA, editors. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press; 2000:237e40.
5. Sohn TA, Yeo CJ, Cameron JL, et al. Intraductal papillary mucinous neoplasms of the pancreas: anupdated experience. Ann Surg. 2004;239(6):788-97.
6. Wada K, Kozarek RA, Traverso LW. Outcomes following resection of invasive and noninvasiveintraductal papillary mucinous neoplasms of the pancreas. Am J Surg. 2005;189(5):632-6.
7. Sohn TA, Yeo CJ, Cameron JL, Iacobuzio-Donahue CA, Hruban RH, Lillemoe KD. Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathologic entity. Ann Surg. 2001;234(3):313-21.
8. Schnelldorfer T, Sarr MG, Nagorney DM, et al. Experience with 208 resections for intraductal papillary mucinous neoplasm of the pancreas. Arch Surg. 2008;143(7):639-46. (Pubitemid 352040228)
9. Nara S, Shimada K, Sakamoto Y, Esaki M, Kosuge T, Hiraoka N. Clinical significance of frozen section analysis during resection of intraductal papillary mucinous neoplasm: should a positive pancreatic margin for adenoma or borderline lesion be resected additionally? J Am Coll Surg. 2009;209:614-621.
10. Crippa S, Fernández-del Castillo C, Salvia R, et al. Mucin-producing neoplasms of the pancreas: an analysis of distinguishing clinical and epidemiologic characteristics. Clin Gastroenterol Hepatol. 2010;8:213-219.
11. Salvia R, Fernandez-del Castillo C, Bassi C, et al. Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection. Ann Surg. 2004;239(5):678-85.
12. Maire F, Hammel P, Terris B, et al. Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma. Gut. 2002;51(5):717-22. (Pubitemid 35216862)
13. Wasif N, Bentrem DJ, Farrell JJ, Ko CY, Hines OJ, Reber HA, et al. Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: a stage-matched comparison of outcomes. Cancer. 2010;116(14):3369-77.
14. Yamaguchi K, Kanemitsu S, Hatori T, et al. Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN. Pancreas. 2011;40(4):571-80.
15. Waters JA, Schnelldorfer T, Aguilar-Saavedra JR, et al. Survival after resection for invasive intraductal papillary mucinous neoplasm and for pancreatic adenocarcinoma: a multi-institutional comparison according to American Joint Committee on Cancer Stage. J Am Coll Surg. 2011;213(2):275-83.
16. Yopp AC, Katabi N, Janakos M, et al. Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas: a matched control study with conventional pancreatic ductal adenocarcinoma. Ann Surg. 2011;253(5):968-74.
17. Poultsides GA, Reddy S, Cameron JL, et al. Histopathologic basis for the favorable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas. Ann Surg. 2010;251(3):470-6.
18. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
19. Japan Pancreas Society. Classification of pancreatic carcinoma. 2nd English ed. Tokyo: Kanehara & Co, Ltd; 2003.
20. Sobin LH, Wittekind C; International Union Against Cancer. TNM classification of malignant tumours. 6th ed. New York: Wiley-Liss; 2002.
21. Fleming ID, Cooper JS, Henson D, et al. AJCC cancer staging manual. 5th ed. New York: Lippincott-Raven; 1997.
22. Schlesselman J, Stolley P. Case-control studies, design, conduct, analysis. New York: Oxford University Press; 1982.
23. Shimada K, Sakamoto Y, Sano T, Kosuge T, Hiraoka N. Invasive carcinoma originating in an intraductal papillary mucinous neoplasm of the pancreas: a clinicopathologic comparison with a common type of invasive ductal carcinoma. Pancreas. 2006;32(3):281-7.
24. Woo SM, Ryu JK, Lee SH, Yoo JW, Park JK, Kim YT, et al. Survival and prognosis of invasive intraductal papillary mucinous neoplasms of the pancreas: comparison with pancreatic ductal adenocarcinoma. Pancreas. 2008;36(1):50-5.
25. Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakashima A, et al. Invasive intraductal papillary-mucinous neoplasm of the pancreas: comparison with pancreatic ductal adenocarcinoma. J Surg Oncol. 2009;100(1):13-8.
26. Mino-Kenudson M, Fernández-del Castillo C, Baba Y, et al. Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes. Gut 2011;60(12):1712-20.
27. Chinn S. A simple method for converting an odds ratio to effect size for use in meta-analysis. Stat Med 2000;19:3127-3131.
28. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
29. Dickersin K, Berlin JA. Meta-analysis: state-of-the-science. Epidermiol Rev. 1992;14:154-176. (Pubitemid 23024558)
30. Kang MJ, Lee KB, Jang JY, Kwon W, Park JW, Chang YR, et al. Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associated IPMN. Pancreas. 2013;42(8):1267-74.
31. Sadakari Y, Ohuchida K, Nakata K, et al. Invasive carcinoma derived from the nonintestinal type intraductal papillary mucinous neoplasm of the pancreas has a poorer prognosis than that derived from the intestinal type. Surgery. 2010;147(6):812-7.
32. Goh BK, Tan YM, Cheow PC, Chung YF, Chow PK, Wong WK, et al. Outcome of distal pancreatectomy for pancreatic adenocarcinoma. Dig Surg. 2008;25(1):32-8. (Pubitemid 351560593)
33. Le H, Ziogas A, Rhee JM, Lee JG, Lipkin SM, Zell JA. A population-based, descriptive analysis of malignant intraductal papillary mucinous neoplasms of the pancreas. Cancer Epidemiol Biomarkers Prev. 2008;17(10):2737-41.
34. Goh BK, Thng CH, Tan DM, et al. Evaluation of the Sendai and 2012 International Consensus Guidelines based on initial cross-sectional imaging findings for the management of mucinous cystic lesions of the pancreas: a single institution experience with 114 surgically-treated patients. Am J Surg. Epub 17 Jan 2014.
35. Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg. 2006;10(9):1199-210.
36. Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg. 1996;223(3):273-279. (Pubitemid 26086718)
37. Konstantinidis IT, Vinuela EF, Tang LH, et al. Incidentally discovered pancreatic intraepithelial neoplasia: what is its clinical significance? Ann Surg Oncol. 2013;20:3643-7.
38. Goh BK, Tan DM, Thng CH, et al. Are the Sendai and Fukuoka consensus guidelines for mucinous neoplasms of the pancreas useful in the initial triage of all suspected pancreatic cystic neoplasms? A single institution experience with 317 surgically-treated patients. Ann Surg Oncol. Epub 7 Feb 2014.
39. Goh BK, Tan DM, Ho MF, Lim KH, Chung AY, Ooi LL. Utility of the Sendai consensus guidelines for branch-duct intraductal papillary mucinous neoplasms: a systematic review. J Gastrointestin Surg. In press.
40. Fritz S, Fernandez-del Castillo C, Mino-Kenudson M, et al. Global genomic analysis of intraductal papillary mucinous neoplasms of the pancreas reveals significant molecular differences compared to ductal adenocarcinoma. Ann Surg. 2009;249(3):440-7.
41. Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology. 2006;6:17-32.
42. Salvia R, Partelli S, Crippa S, et al. Intraductal papillary mucinous neoplasms of the pancreas with multifocal involvement of branch ducts. Am J Surg. 2009;198(5):709-14.
43. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007;297(3):267-77. (Pubitemid 46143304)
44. Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473-1481.